Implicit in many studies of thyroidal function is the assumption that the rates of synthesis and degradation of thyroid hormone are equal (1-4). Yet this assumption has not been critically examined. Constancy of concentrations of serum precipitable iodine (SPI), particularly under conditions of environmental stress, need not indicate an equilibrium of this type, for interposed between the site of hormonal synthesis and the peripheral circulation is a large pool of stored hormone (1, (4) (5) (6) . This pool is capable of maintaining, at least for a time, constancy of SPI, despite marked discrepancies between rates of hormonal production and degradation (7).
Implicit in many studies of thyroidal function is the assumption that the rates of synthesis and degradation of thyroid hormone are equal (1) (2) (3) (4) . Yet this assumption has not been critically examined. Constancy of concentrations of serum precipitable iodine (SPI), particularly under conditions of environmental stress, need not indicate an equilibrium of this type, for interposed between the site of hormonal synthesis and the peripheral circulation is a large pool of stored hormone (1, (4) (5) (6) . This pool is capable of maintaining, at least for a time, constancy of SPI, despite marked discrepancies between rates of hormonal production and degradation (7) .
A method has been devised for simultaneous estimation of the rate of degradation of thyroxine within the body and the rate of iodination of organic moieties within the thyroid gland.4 The equivalence of these two functions has been assessed in patients with diverse thyroidal states. In addition, the method has been applied to an evaluation of several factors which influence the degradation of thyroxine.
MATERIAL AND ANALYTIC METHODS
The group studied included nine euthyroid individuals, five patients with untreated myxedema, nine with treated 1 This investigation was supported in part 3 Fellow of the American Cancer Society, Inc., recommended by the Committee on Growth of the National Research Council. 4In the ensuing discussion, iodinated organic moieties stored within the thyroid gland, regardless of their specific chemical nature, will be termed "thyroid hormone." myxedema, five with -Graves' disease, and three with panhypopituitarism. Diagnoses were established on the basis of clinical picture, determination of BMR, thyroidal uptake of IX, SPI, and when necessary, measurements of adrenal and pituitary gonadorophic function. All patients were studied on a metabolic ward, receiving constant weighed diets ranging from 2,000 to 4,000 in caloric content.
Each patient received from 3 to 5 tg. of l-thyroxine intravenously,5 labelled with 30 to 50 i'c of In. At 24hour intervals the thyroidal content of radioiodine was measured with a directional scintillation counter (sodium iodide crystal, thallium activated) positioned 20 on from the neck. Radioactivity over the midthigh was subtracted from that observed over the neck in order to "correct" for extrathyroidal radioactivity. Samples of serum and 24-hour collections of urine were obtained daily in carefully cleaned glassware. In patients with thyrotoxicosis, samples of serum were obtained twice daily. In patients in whom fecal collections were made, powdered carmine was used as a marker. Weighed aliquots of homogenized stool were prepared. Radioactivity in all samples of serum, urine, and feces was determined in a well-type scintillation counter (sodium iodide crystal, thallium activated), and in all instances was expressed as a percentage of the administered dose. Corrections for physical decay were obviated by comparing the activity of all samples to that of a suitably diluted fraction of the administered dose. Sufficient counts were observed to reduce the probable error of results to less than one per cent. Analyses for stable iodine were performed by the method of Barker, Humphrey, and Soley in serum (8) and the method of Barker in urine (9).6 Statistical analyses were performed according to methods described by Snedecor (10) .
METHOD OF ANALYSIS
Following the intravenous administration of radioactive thyroxine (Tx*), the virtual volume of distribution of injected material was calculated daily according to the principle employed by Myant and Pochin and by Benua, Albert, and Keating in the study of the distribution of radiothyroxine in man (11, 12 Avenue, Los Angeles 64, Calif. TDS = The "thyroxine distribution space" or volume of distribution of thyroxine at any time, t (liters). R = Residual radiothyroxine (Per cent of the administered radiothyroxine remaining within the thyroxine space at any time, t. Total dose minus sum of thyroidal, fecal and urinary collections of I' up to time, t). P = Concentration of Tx* in plasma at time, t (per cent dose per liter). TDS = R/P. Mixing of Tx* was assumed to be complete when calculated values of TDS became constant The subsequent slope of the exponential curve depicting the concentration of Tx* in the plasma was considered to represent solely the metabolism of labelled hormone. The time required for the concentration of isotope to decrease by 50 per cent (half-time, t'/) was determined by inspection of the metabolic slope, and the fractional rate of turnover of thyroxine (k) was calculated according to the formula, k (proportion/day) = 0.693/t' (days).
In addition, where V = Daily volume turnover or the volume of the TDS whose hormone is replaced daily (liters per day). ETT = Extrathyroidal thyroxine. Thyroxine contained within the TDS (ptg. thyroxine I). V=TDSXk ETT=TDS X SPI X 10 D=VX SPIX 10. During the degradation of radioactive thyroxine, radioiodine accumulates in three sites: the thyroid, urine, and feces ( Figure 1 ). That within the urine and thyroid has been demonstrated to arise principally from inorganic I' liberated by the peripheral degradation of thyroid hormone (11) (12) (13) . Fecal radioactivity has been shown to be largely organic (13) . The plasma's radioactivity was considered to consist entirely of Tx*. However, since inorganic radioiodine must certainly have entered thyroid and urine from the plasma, a fraction of the plasma's radioiodine must at all times have been inorganic. Previous authors have considered this fraction to be negligibly small (11) (12) (13) . One estimate of the magnitude of this inorganic moiety could be derived by substituting in the conventional clearance formula the daily excretion of radioiodide and an assumed daily renal iodide clearance of 48 liters (11) . Inorganic radioactivity in plasma was found by this technique to contribute no more than 1 to 2 per cent to the total radioactivity of plasma. Furthermore, in 11 patients, 93 to 99 Since the rate of removal of iodide from the plasma exceeds greatly the rate of degradation of thyroxine, it was anticipated that, as Berson, Yalow, Schreiber, and Post have demonstrated for iodinated human serum albumin (14) , the rate of entry of radioiodide into thyroid or urine would be governed by the rate of breakdown of administered Tx*. Both the urinary and thyroidal accumulation of radioiodine should therefore approach a maximum at the same exponential rate at which the concentration of Tx* in plasma approaches a minimum (15) . The daily increment in thyroidal and urinary radioiodine should diminish at the same exponential rate as does the concentration of Tx* mi plasma. This proved to be the case. It therefore became possible to calculate, from data collected over a 10 to 16-day period, theoretical values for the ultimate (t=00) thyroidal and urinary accumulation of I=. Two points in time subsequent to completion of mixing of Tx* are chosen. As has.been demonstrated following the administration of inorganic 1 (15).
SCHEMA OF THE DiSTRIBUTION FATE OF A SINGLE DOSE OF

THYROXINE-I'3' DISPLAYING DELAYED MIXING
USES-Us P'
UKA., -U2 P2 This equation may be solved for its one unknown, UA.,.
The values of (U. -UJ) and (Um.A-U.), when plotted against time, define an exponential curve, parallel to the curve of the plasma's concentration of Tx*. Accuracy of collections, as well as calculation can be ascertained by plotting all observed values against this curve ( Figure 2 ). The zero-time intercept of this curve should equal Uu,. However, since mixing of injected Tx* is not instantaneous, metabolism of radiothyroxine and excretion of I' may be excessive prior to the completion of mixing, when the concentration of Tx* in plasma is inordinately great. The magnitude of this excessive or disproportionate loss of radioiodide into the urine will be reflected by the amount by which the zero-time intercept falls short of USA.
Similar calculations can be made with values of thyroidal I`. Since the total dose of radioiodine eventually appears in thyroid, urine, or feces, it then becomes possible to calculate by the following formula a theoretical maximum feal collection of I' (Few). F1az = 100-(Uma + Tuxu). Complete results will be presented in a subsequent publication.
t Days after administration of radiothyroxine.
It may be assumed that fecal collection of Im proceeds at the same exponential rate as loss of Tx* from the plasma. This assumption is borne out by the data of Benua, Albert, and Keating (12) . Cumulative fecal loss at any time (Ft) may therefore be calculated according to the following formula. Ft = Fu. (1 -ekt). The accuracy of determining fecal: excretion of radioiodine in this indirect manner was checked in 10 instances (Table I ). In no case did calculated and observed values differ by more than 2.4 per cent of the administered dose. Because of the difficulties inherent in accurately collecting and measuring radioactivity in daily fecal samples, the indirect method was utilized in subsequent patients.
Estimates of the mean daily production of thyroid hormone were made in the following manner. From each daily urinary collection, a standard percentage (1 per cent) was pooled with similar fractions from previous days. Analysis of the pooled urinary samples revealed the geometrical mean of the concentration of I' during the period of observation. The product of this value and the mean daily urinary volume revealed the average daily excretion of stable iodine. The increase in thyroidal and urinary collections of I' (AT and AU) between the completion of mixing of Tx* and completion of the study was determined by inspection of appropriate accumulation curves. By the time mixing is complete negligible quantities of organic I' are present in the urine (11) . It has further been demonstrated that following the administration of Tx*, the relative rates of entry of radioiodine into thyroid and urine are the same as those which follow the administration of inorganic Pm. These in turn may be considered to represent the relative rates of entry of inorganic If' into these two sites (11, 12) . Therefore, AU daily urinary excretion of IP"
AT daily thyroidal accumulation of I"2
This equation is then solved for its one unkown, the daily thyroidal accumulation of In', or rate of production of hormone.
Observation of the urinary and thyroidal accumulation of I' following the administration of radiothyroxine also makes possible calculation of the fraction of liberated radioiodide which enters the thyroid gland. This has been designated the thyroidal fraction (T.F.).
AT X 100
T.F. (per cent) = AT
Since radioiodide liberated by the peripheral degradation of Tx* apportions itself between thyroid and urine as does a tracer dose of inorganic radioiodide, the thy-roiWal fraction should be numerically equal to the ultimate thyroidal uptake of a tracer dose of inorganic Ia. In 10 patients, values of the thyroidal fraction were compared with the uptake observed 48 hours after a usual tracer dose of radioiodide. In no instance did the thyroidal fraction differ from the observed uptake by more than 5.3 per cent of the administered dose; the mean difference between the two being 0.2 per cent uptake (Table  II) . The close agreement noted between predicted and observed values of the radioiodide uptake would appear to confirm both the accuracy of collections and measurements as well as the basic assumptions upon which the method depends.
RESULTS
Euthyroidism: (Table III .) The SPI in normal patients ranged from 3.0 to 7.0 ug. per cent. Thyroxine was found to be distributed in an average volume of 9.4 L. and to be replaced at an average rate of 10.6 per cent per day. Mean voltq Treated myzedema: All patients were judged to be euthyroid on the basis of clinical picture and BMR. SPI in this group ranged between 3.2 and 9.0 pg. per cent. Values for all functions agreed well with those of the euthyroid group.
Primary myzedema: In the five subjects comprising this category, SPI ranged from 1.1 to 2.5 pg. per cent. A significant reduction of the TDS was observed (mean, 7.5 L.; p < .02). Although the fractional rate of turnover of thyroxine was somewhat less than normal, a statistically significant reduction could not be demonstrated. As a result of the diminution in these functions, the average daily volume turnover of the thyroxine space was significantly reduced (mean, 725 ml.; p < .01). Similarly total extrathyroidal thyroxine (mean, 10.7 pg. I; p < .01) and the daily rate of utilization of thyroxine (mean, 10.7 pg I per day; p < .01) were significantly less than normal.
Panhypopituitarism: Because of the small number of patients available for study, statistical analysis of results in this group was not carried out. The distribution and rate of turnover of thyroxine appeared to be similar to that observed in patients with untreated myxedema, but SPI was uniformly greater, and consequently, utilization of hormone, although subnormal, was considerably more than that encountered in the myxedematous group.
Hyperthyroidism: Studies were performed in four patients with untreated hyperthyroidism whose SPI's ranged from 14.6 to 17.5 pg. per cent. For the following reasons, other results in this group must be considered approximations of those which truly pertain. Radioiodine liberated by the peripheral degradation of thyroxine is apportioned between the thyroid and the urine. In patients with thyrotoxicosis, the larger fraction of this inorganic radioiodide enters the thyroid gland. Once incorporated into hormone, the radioiodine is rapidly released into the circulation (1, 16) . The accelerated turnover of radioiodine in the thyrotoxic gland results in a progressive underestimation of the thyroidal accumulation of Il81 and in a restoration to the thyroxine space of a portion of the radiothyroxine initially injected. Thus, there results an overestimation of the plasma's concentration of exogenously administered Tx* and an underestimation of the rapidity of its degradation. Finally, as the endogenously synthesized radiothyroxine is degraded, a fraction of the radioiodide thereby liberated will also enter the urine and hence will augment the urinary radioactivity resulting from the initial cycling of Tx*.
That this sequence of events did transpire in patients with untreated thyrotoxicosis is suggested by the following observations. In contrast to the findings of patients in other clinical categories, in whom a continuously increasing thyroidal content of 18l was noted, thyroidal radioactivity increased during the first several days after administration of Tx*, and then either decreased or remained constant. Similar curves of the thyroidal accumulation of Il31 following the administration of Tx* to hyperthyroid patients have been noted by Benua, Albert, and Keating (12) . When the daily increment in thyroidal Il31 during the first several days was plotted, an exponential curve with a slope parallel to that of the plasma's concentration of Tx* was defined. Subsequent points, however, fell progressively below a projection of the initial slope.
It is well known that radioactive hormone may be released from the thyroid gland within a few hours after the initial penetration of inorganic I1s' (17) . However, in the present system, the earliest gross manifestation of hormonal release was the appearance of a deficit in the thyroidal increment of radioiodine, as noted above. This was mirrored in the urine by an excessively large daily increment in Il31 and in the plasma by a retardation of the rate of disappearance of radiothyroxine.
If endogenously synthesized radiothyroxine were instantaneously mixed throughout its distribution compartment, these events would not alter values of TDS obtained by the present method, which relates the amount of Tx* within the thyroxine space to its concentration therein. Only the observed fractional rate of turnover would be affected (decreased). However, mixing of thyroxine is not instantaneous. As a consequence, the magnitude and direction of errors in the estimation of the thyroxine space will depend upon two factors: a) The relative rapidities of hormonal turnover within the gland and hormonal mixing within the thyroxine space, and b) alterations in fecal losses resulting from retardation of 813 the net disappearance of thyroxine from the plasma.
Despite the foregoing difficulties, an attempt was made to derive approximate values in hyperthyroid patients by the method described. Calculations were based on data obtained only during the interval between the completion of mixing of administered radiothyroxine (i.e., subsequent to 24 hours) and the first gross manifestation of release of radioactive hormone from the thyroid gland (72 to 120 hours).
The mean TDS of hyperthyroid patients did not appear to differ significantly from the normal value. The fractional rate of turnover was, however, markedly augmented (mean, 24.39 per cent per day; p < .01) as was daily volume turnover (mean 2,129 ml. per day ; p < .02). SPI ranged from 14.6 to 17.5 pg. per cent. Total extrathyroidal thyroxine (mean, 1544 pg. I; p < .05) and daily rate of utilization of thyroxine (mean, 359 pg. I; p < .01) were significantly greater than normal.
Since only early data were used in these calculations, it remained possible that the apparently rapid turnover rate might in part represent continued mixing of injected Tx*. Therefore, one untreated patient (M. T.) with thyrotoxicosis was given 300 mg. of propylthiouracil and 30 drops of Lugol's solution daily during the determination of his rate of degradation of thyroxine.7 This medication completely inhibited the thyroidal accumulation of radioiodine, and thereby prevented the recycling of radiothyroxine. Despite the fact that the patient experienced rapid and nearly complete symptomatic response during the period of observation, the fractional rate of turnover of thyroxine was more rapid than that noted in any non-hyperthyroid patient, and fell near the range noted in other hyperthyroid patients who received no antithyroid therapy. Production roidal accumulation of radioiodine and conse-t quently measurable thyroidal production of hormone could not be demonstrated in patients with primary myxedema. Patient V. M. has for years displayed classical signs and symptoms of hypothyroidism, together with abnormally low BMR and SPI, despite 24-hour thyroidal uptakes of I111 ranging from 40 to 50 per cent. The present studies revealed a normal rate of production of hormone, an abnormally low rate of degradation of thyroxine, and a diminished SPI. Preliminary studies in this patient suggest that her thyroid gland is producing and releasing into the circulation both thyroxine and a calorigenically less potent iodinated derivative whose solubility characteristics differ from those of thyroxine. Relation between production of thyroid hormone and degradation of thyroxine: In individual patients with normal thyroidal function or panhypopituitarism, concomitantly measured rates of production of thyroid hormone and degradation of thyroxine were closely correlated (r = 0.84 + 0.19, p = .002). Analysis by the "paired t" test revealed no significant difference between paired values in individual patients (p > 0.2). In only one patient, A. B., a 45-year old alcoholic man with slowly resolving pneumonia, did paired values differ markedly. Although several patients in the normal group had recently been ill, A. B. was the only patient who had not convalesced completely at the time of study.
In thyrotoxic patients, calculated values for the daily production of hormone averaged 890 ,ug. and consistently exceeded estimates of the daily degradation of thyroxine.
DISCUSSION
Disappearance of hormone may reflect either a) utilization specifically associated with its action on an end organ, or b) degradation which is not linked to the mechanism of hormonal action. Since no known method will differentiate between these possibilities with regard to thyroid hormone, solely the term degradation is used herein to denote overall disappearance of thyroxine from its compartment of distribution.
Several previous studies of the degradation of radioactive thyroxine have employed conventional extrapolation techniques (3, (18) (19) (20) . Potential errors of this technique are well known, and may 814 THYROXINE DEGRADATION A"d THYROID HORMONE SYNTHESIS influence both the measured space' a'nd-the turn-Daily volume turnover of thyroxine did not difover rate (14, 21 )* These errors arise as a result fer significantly among patients with normal thyof disproportionate metabolism of the labelled' reidal function, treated myxedema, and panhypometabolite during the mixing period, failure to ohpituitarism. In patients with untreated myxserve the plasma's slope for a sufficiently long' edema, this function was reduced by about 25 per period, and nonhomogeneity of the injected' ma-cent. Nevertheless,? th large differences between terial.
the rates of degradatiQn -mong these non-thyro-The present method seeks to avoid these er-toxic groups were' largely conditioned by and prorors. The virtual volume of distribution of thy-portional to differences in the SPI. In the thyroroxine at any time may be calculated as the quo-toxic patients, degradation was not proportional tient of the Tx* remaining in the space and its solely to the SPI, since the fractional turnover concentration therein. Rapidly metabolized conrate and therefore the daily volume turnover were taminants, once cleared from the space, do not markedly augmented (Figure 3 ). Proportional therefore influence the results. Constancy of calutilization of thyroxine, together with moderate culated volumes of distribution indicates that mix-reduction in the daily volume turnover of myxing has been completed, and that the fractional edematous patients may explain the relative ease rate of degradation may then be determined from with which the SPI can be elevated by standard the subsequent slope of the curve depicting the doses of desiccated thyroid when the SPI is low, concentration of Tx* in the plasma. compared with the relative difficulty encountered By means of the present technique, the mean in augmenting SPI when its concentration is nornormal rate of degradation of thyroxine was found mal or increased (23). Furthermore, it may be to be 53.6 pg. thyroxine iodine per day in normal surmised that the disproportionately rapid degrasubjects and 47.5 M1g. thyroxine iodine per day in dation of thyroxine in the hyperthyroid patient, euthyroid patients with treated myxedema. These resulting from an increased fractional rate of turnvalues agree with estimates of the daily requireover, would tend to lower the SPI and to make ment for hormone which others have derived, us-this measurement a rather insensitive index of ing a variety of methods (4, 20, 22) . the quantity of hormone used. It may further As might be anticipated, breakdown of thyrox-be noted that the relationship between SPI and ine was considerably increased in thyrotoxic sub-degradation of thyroxine depicted in Figure 3 jects and profoundly diminished in patients with closely approximates the relationship between untreated myxedema. Values intermediate be-SPI and hormonal production and degradation, tween those obtained in the euthyroid and the described by Burrows and Ross (24) and by myxedematous groups were derived in patients Berson and Yalow (4), respectively. with panhypopituitarism.
Several further inferences concerning the metab-An examination of the constituent functions olism of thyroxine may be drawn from the forereveals the sources of differences in degradation going data. When administered torats, large of thyroxine noted. In normal patients thyroxine doses of thyroxine labelled with I'l31 are more distributed in a volume of approximately 9.4 L. rapidly metabolized than are small doses (25, 26). Approximately 10 per cent of the thyroxine con-An analogy may therefore be sought in the rapid tained within the space was replaced by newly re-disappearance of thyroxine from the plasma of leased hormone each day. The thyroxine con-thyrotoxic patients. The more rapid removal of tained within approximately 1,000 ml. of the space thyroxine under these circumstances could be was renewed each day. In myxedematous pa-ascribed to detoxification, perhaps performed by tients, the volume of the TDS was significantly the liver (26-28). Although the present method diminished, and the fractional rate of turnover of does not ascertain the ultimate metabolic fate of Tx* was slightly reduced. As'noted above, re-thyroxine, it does permit evaluation of the relasults in patients with hyperthyroidism must be tive quantity of hormonal iodine which is reduced interpreted with some reservations. Nevertheless, to inorganic iodine and that which is excreted in the TDS did not appear to differ from normal in the organic form via the feces. Normally approxipatients with this disease. mately 25 per cent of' I'll administered as Tx* However, in the non-thyrotoxic range, the relationship approaches linearity. appears in the feces, the remainder entering the thyroid or urine. In the hyperthyroid patient given radiothyroxine, this apportionment between fecal and non-fecal moieties did not differ significantly from the normal.
It has recently been suggested that augmented salivary deiodination of compounds containing organically bound iodine may occur in myxedema, and that salivary deiodination mechanisms, perhaps under hypophyseal control, may serve to maintain the balance of thyroid hormone in the body (29-31). There is ample evidence which the present study supplements, that thyroxine is the principle iodinated compound released by the thyroid gland. A predicated enhancement of deiodination in patients with myxedema is clearly not consistent with the observation that the fractional rate of turnover of thyroxine in such patients is, if anything, slower than that found in patients with normal thyroidal function or with treated myxedema.
The precise anatomical limits of the thyroxine space obviously cannot be defined. However, the values noted above for the distribution and rate of turnover of thyroxine are similar in magnitude to those previously reported for certain of the pro-teins in plasma (14, (32) (33) (34) . In plasma, thyroxine is bound to an a-globulin (35) (36) (37) . One may wonder whether the distribution and fate of thyroxine are related to the fate of the protein to which it is bound. The reduction in TDS in patients with untreated myxedema might there be analogous to the reduction in myxedema of the volume of dilution of dyes whose distribution is limited by their protein carrier (38). Similarly, alteration in the rate of turnover of thyroxine in patients with myxedema or thyrotoxicosis would then be consistent with parallel alterations in the rate of turnover of protein and other metabolites in these diseases (3941). Studies designed to evaluate this hypothesis are in progress. However, preliminary observations suggest that the abnormally rapid removal of thyroxine seen in hyperthyroid patients may persist for months following the complete amelioration of the thyrotoxic state (7) . The relationship of this metabolic abnormality to the inception or continuance of the disease state obviously remains to be clarified.
Although the present data do not make possible an appraisal of the metabolic fate and calorigenic importance of all iodinated compounds contained in thyroid extract virtual equivalence between intake of exogenous thyroxine and degradation of this hormone. In six athyreotic patients under therapy with thyroid extract, an average of 21.0 pg. thyroxine iodine was degraded per grain of U.S.P. thyroid extract administered (Table IV) The present method does not necessitate inhibition of thyroidal accumulation of radioiodide liberated by the peripheral degradation of Tx*, and thus makes possible estimation of the relative rates of entry of inorganic iodide into thyroid and urine. Hence, measurements of the daily excretion of stable iodine may be used to calculate the daily thyroidal accumulation of I127, or rate of production of hormone. In individual non-thyrotoxic subjects, close agreement has been noted between the daily incorporation of I127 into organic moieties and the concomitantly measured daily degradation of thyroxine (Figure 4 ).
Production and utilization of hormone in patients with panhypopituitarism although less than normal, exceeded considerably that found in patients with primary myxedema. The present data, which are apparently the first measurements of absolute rates of production of thyroid hormone in patients with pituitary myxedema, substantiate the lesser severity of myxedema arising from pituitary rather than from thyroidal failure.
In patients with hyperthyroidism, calculated values for the rate of production of thyroid hormone markedly exceeded values of the rate of degradation of thyroxine. This discrepancy could result from several factors. First, disparate values might represent a methodological artifact. Since, in thyrotoxic patients, the rapid turnover of iodine results in a diminution in the apparent thyroidal accumulation and an increase in the urinary excretion of I's', it might be anticipated that rates of production of hormone would be underestimated. However, it is likely that rates of degradation are also underestimated. As noted earlier, release of radioactive hormone from the hyperfunctioning thyroid gland is rapid, and significant quantities of newly synthesized radiothyroxine may certainly have entered the circulation by the time mixing of exogenous Tx* was complete. It is likely that even the early slopes of disappearance of Tx* from plasma were slowed, and rates of degradation therefore underestimated. The relative magnitudes of these errors in the estimation of production and degradation cannot be assessed.
Alternatively, the observations may reflect a true disparity. Repletion of glandular stores of stable iodine during the period of observation (10 to 16 days) might be one of the means whereby thyroidal incorporation of iodine could exceed the peripheral -degradation of thyroxine. Smlarly, release from the gland of quantities of thyroxine in excess of those being removed fronm the circulation could also be invoked. Although values of the SPI remained constant during the period of study, more prolonged-observation might have revealed an increase.in the concentration of circulating hormone. Another possible an would be-the synthesis and release if iodinated compounds other Athan. thyroxine-Such compounds, e.g., triiodothyronine, which ave. widely distributed and rapidly metabolized (18, 20) , would be expected to contribute but little. to circulating protein-bound iodine. Unfortunately, available.data does not permit differentiation between these or. other alternatives.
The-present data demonstrate for the first time a close correlation between the rate of degradation of thyroxine and the rate of incorporation of iodine by the thyroid gland of the non-thyrotoxic patient. If, on the one hand, thyroxine is the principal iodinated compound produced and released by the thyroid gland, it may be concluded that mean glandular content of iodine remains constant over a period of 10 to 16 days. On the other hand, if it be assumed that glandular thyroxine remains constant, then thyroxine must constitute the principal end-product of thyroidal organic iodinations. One cannot logically conclude that either premise is necessarily true. However, their equivalence has been demonstrated by the present findings, and hence validation of both premises requires merely the verification of one. SUMMARY 1. A method has been described which makes possible the simultaneous estimation of the rate of degradation of thyroxine and the rate. of synthesis of thyroid hormone.
2. In non-thyrotoxic patients, a close agreement between values of these functions has been noted.
3. Factors influencing the distribution and fate of thyroxine in diverse states of thyroidal function have been evaluated.
